Close
FR

Information

The content of this site is reserved for healthcare professionals, in accordance with Law No. 2011-2012 of December 29, 2011 relating to strengthening the health safety of medicines and health products, including the implementing decree relating to the advertising.

By clicking on OK, you confirm that you are a healthcare professional.

ACCEPT
close

Spontaneous application form





















    We use cookies to give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

    About

    In 2009, two physician-researchers, Dr. Erwan L’Her (head of the intensive care unit and INSERM researcher at the University Hospital of Brest) and Dr. François Lellouche (intensivist and researcher at the QHLI) joined forces after a clinical research project to develop a device to automate the administration of oxygen therapy. They founded OxyNov Inc to focus entirely on developing the FreeO2 device, thus improving the application of this treatment on a daily basis.

    OxyNov started up at the Quebec Heart and Lung Institute (QHLI) with the support of all pulmonologists. The team was aware of the daily challenge that applying the clinical recommendations represented for healthcare staff and firmly believed in the medical benefits of the solution.

    Prototype developed at Laval University; OxyNov founded by Dr. Erwan L’Her and Dr. François Lellouche

    Prototype developed further

    Commercial device finalized

    CE marking obtained

    Device approved by Health Canada

    FreeO2 enters the spotlight due to the pandemic

    Press conference held with the QHLI and the City of Quebec to present FreeO2 to the general public

    Mission

    Our mission is to overcome the current limitations of respiratory care and change clinical practice to improve the safety and quality of life of patients and optimize care in a context of an increasing number of patients and of hospitalization cost control. We are and will remain pioneers in oxygen therapy.

    Vision

    Provide powerful, innovative, and cutting-edge technology to advance oxygen therapy by preventing hyperoxia and hypoxemia and significantly improving cardiopulmonary monitoring in patients.


    Values

    Work with integrity by actively listening to patients and healthcare professionals and creating a culture of innovation that allows us to remain pioneers in reimagined, improved oxygen therapy.


    OUR MANAGEMENT

    A seasoned administrator and President and CEO of Sogealpha Inc., Jean-Pierre Robert is an internationally recognized ambassador of medical innovations and a well-known leader in the pharmaceutical and medical device fields.

    JEAN-PIERRE ROBERT

    CHAIRMAN OF THE BOARD

    Patrice Allibert has 35 years of experience in the medical devices and animal health fields. He is responsible for launching a number of platforms and tests, all CE-IVD certified, FDA cleared, or USDA cleared . He is the former CEO of GenePOC and Vice President of R&D and Innovation of BD. His current and recent board experience includes ImmunExpress, FOLIA BioTech, and the Canadian Institute of Health Research.

    PATRICE ALLIBERT

    CEO OF OXYNOV

    Dr. Lellouche is the co-inventor of FreeO2 and an intensivist and researcher specializing in the respiratory field at the Quebec Heart and Lung Institute. His areas of research include the automation of oxygen therapy and mechanical ventilation, innovation in respiratory support and monitoring, automated high-flow NIV devices, and respiratory humidification.

    DR FRANÇOIS LELLOUCHE

    CO-FOUNDER OF OXYNOV

    Dr. L’Her is the co-inventor of FreeO2, an intensive care pulmonologist, an INSERM researcher specializing in the respiratory field, and head of intensive care medicine and reanimation at the Brest University Hospital. He is also the chief national scientist of the IDEFI (Initiatives d’excellence en formations innovantes) program in the REMIS network, head researcher at the INSERM’s LaTIM laboratory, and professor of research in pulmonology and the respiratory field.

    DR ERWAN L’HER

    CO-FOUNDER OF OXYNOV

    PARTNERS